Kerala HC: Applications under the Muslim Women’s Divorce Act Have a 3-Year Limitation Period  ||  Supreme Court: Property Transferred Before Filing a Suit Cannot be Attached under Order 38 Rule 5  ||  Supreme Court: No Review or Appeal is Maintainable Against an Order Appointing an Arbitrator  ||  SC: Terminated Contract is Not a Corporate Debtor’s Asset and a Moratorium Cannot Revive it  ||  SC: Cheque Dishonour Complaints Must be Filed at the Payee’s Home Branch under S.142(2)(A)  ||  Supreme Court: Bail Cannot be Granted Solely on Parity; Accused’s Specific Role Must be Assessed  ||  Kerala HC Upholds Life Terms For Five, Acquits Two in Renjith Johnson Murder, Says TIP Not Needed  ||  Kerala HC Orders Emergency Electric Fencing at Tribal School to Address Rising Wildlife Conflict  ||  Madras HC: Arbitrator Can’t Pierce Corporate Veil to Bind Non-Signatory and Partly Sets Aside Award  ||  Calcutta HC: Post-Award Claim For Municipal Tax Reimbursement is Not Maintainable under Section 9    

Roche Products v. Drugs Controller General of India and ors - (High Court of Delhi) (25 Apr 2016)

Delhi High Court to delve into Drug Controller irregularities

Civil

The Delhi High Court deferred a dispute regarding the development, classification and promotion of bio-similar drugs to 2 June 2016. Brought by Roche Products, the plaint raised concerns about irregularities by the Drug Controller General of India in granting approval to Biocon Limited and Mylan Pharmaceuticals for a bio-similar drug in five days - a process which usually takes much longer than that due to deliberation by three separate bodies, before it reaches the DCGI. The drug in question is Trastuzumab, used for treatment of breast cancer.

The Court accepted Roche’s arguments, ruling that “approvals…are not on the basis of the adherence of the Guidelines of 2012 and rules framed”. However, final finding would be arrived at upon completion of trial. The Defendants were allowed to continue manufacturing and marketing their drug claiming bio-similarity with Roche’s drug, but with certain provisos on indication used on packaging.

Tags : TRASTUZUMAB   BIO-SIMILAR   DCGI   ROCHE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved